PARIS -- The initial Late Breaking Trial Session at EuroPCR 2018 summarized a series of trials assessing the utility of physiology within the treatment strategy to help guide the usage of percutaneous coronary intervention (PCI) for chronic coronary syndrome (CCS) patients